Gilead Gets Lenacapavir To EU Approval For HIV Salvage Therapy, Awaits FDA’s Call

A first-in-class capsid inhibitor, lenacapavir is a linchpin of Gilead’s long-term strategy in HIV treatment and prevention, but has faced regulatory setbacks in the US.

Gilead HQ
Gilead gets first of what it hopes will be many lenacapavir approvals • Source: Shutterstock: Sundry Photography

Gilead Sciences, Inc. has endured some setbacks in bringing its first-in-class capsid inhibitor lenacapavir to the finish line, but with a marketing authorization from the European Medicines Agency on 19 August the biopharma may be on the way to realizing its broad ambitions for the long-acting oral or injectable drug. Branded as Sunlenca, the drug’s initial approval is as part of combination therapy in multi-drug-resistant HIV patients who cannot achieve viral suppression with another regimen.

[Sidebar#SC143338]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By 

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.